MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AIM ImmunoTech Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M. Mitchell
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group’s Nominees to the Board
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Refutes Activist Group’s False and Misleading Claims
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Announces Cash Conservation Plan
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
From AIM ImmunoTech Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story